MLN3701

MLN3701 is an investigational, orally administered small molecule inhibitor of the PIM (Proviral Integration site in Moloney murine leukemia virus) family of serine/threonine kinases, specifically targeting PIM-1, PIM-2, and PIM-3. Developed by Millennium Pharmaceuticals (a subsidiary of Takeda), MLN3701 was designed to disrupt the PIM signaling pathway, which is frequently overexpressed in various hematological malignancies and solid tumors, contributing to cell survival, proliferation, and resistance to apoptosis. By competitively inhibiting the ATP-binding site of PIM kinases, the compound prevents the phosphorylation of downstream substrates involved in protein synthesis (such as 4E-BP1) and cell cycle regulation (such as p21 and p27), thereby inducing cell cycle arrest and apoptosis in cancer cells. Clinical development reached Phase 1 dose-escalation studies in patients with advanced solid tumors and lymphoid malignancies, though the program was subsequently terminated.

Other names

PIM kinase inhibitor MLN3701